secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001711279-24-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q1 2024 net income $0.9M; VYJUVEK revenue $45.3M; cash $622M
----------------------------------------------------------------------------

- Net income $0.9M ($0.03 EPS) vs net loss $45.3M ($1.76 loss) in Q1 2023.
- VYJUVEK net product revenue $45.3M, gross margin 95%, patient compliance 91%.
- Cash $622.3M; FY 2024 Non-GAAP R&D+SG&A guidance $150M-$175M.
- Pipeline: KB408 AATD first patient; KB407 CF Cohort 2 complete; inhaled KB707 first patient; intratumoral KB707 Cohort 3 enrolled.
- Regulatory: European MAA decision and GMP certification expected 2H 2024; Japan NDA filing target 2H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/0001711279-24-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000018/krys-20240506.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer